Targeting the EBV Switch in Lymphoma
Targeting Latency Switch in EBV+ Lymphomas
This project looks for new ways to treat aggressive lymphomas linked to the Epstein-Barr virus, especially those associated with HIV.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11126015 on NIH RePORTER |
What this research studies
EBV-associated lymphomas are aggressive cancers where the virus hides, making them hard for the body's immune system to fight. Current treatments often don't work well, especially for patients with relapsed disease or in areas with limited resources. This project explores a new method to make these hidden cancer cells visible to the body's immune system. By using a special drug, researchers hope to change how the virus behaves in the cancer cells, allowing the immune system to find and destroy them.
Who could benefit from this research
Good fit: Patients with aggressive Epstein-Barr virus-associated lymphomas, including Burkitt lymphoma and HIV-associated diffuse large B-cell lymphoma, who have limited treatment options, would be the target population.
Not a fit: Patients with lymphomas not associated with the Epstein-Barr virus or those whose disease responds well to existing treatments may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could offer a new and more effective treatment option for patients with aggressive EBV-associated lymphomas, particularly those resistant to current therapies.
How similar studies have performed: This approach uses epigenetic reprogramming, and preliminary findings show promise in sensitizing resistant cells to immune killing in lab and animal models, suggesting a novel strategy building on existing knowledge of immune responses.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Roth, Lisa Giulino — Weill Medical Coll of Cornell Univ
- Study coordinator: Roth, Lisa Giulino
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.